AlphAIAlphAI — Financial news for AI agents
pymnts.comOCT 122 min read$TEVA

Corcept Seeks to Block Ex-Judge’s Testimony in Teva Antitrust

Corcept Therapeutics (CORT) is challenging the testimony of retired judge Kathleen O’Malley in its ongoing antitrust lawsuit with Teva Pharmaceutical (TEVA). Corcept argues O’Malley’s testimony improperly addresses legal questions for the jury. Teva accuses Corcept of using patent litigation to block generic competition for its drug Korlym, seeking financial compensation and injunctive relief. The trial is scheduled for March 2027, with Corcept denying the allegations.

Original reporting
pymnts.com
Published Oct 12, 2026, 8:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Corcept Seeks to Block Ex-Judge’s Testimony in Teva Antitrust — source image
Source · pymnts.com
Decision brief

The 30-second read

$TEVABullishLow
01

Why it matters

The court's decision could shift the balance of the litigation, influencing both companies' stock valuations.

02

Market read

A procedural filing that may affect the outcome of a high‑stakes antitrust case, with modest but immediate relevance to the two stocks.

03

What to watch

Potential settlement discussions or parallel regulatory actions could change the litigation dynamics.

Relevance 6/10Novelty 6/10Timing: pre-trial period before March 2027 trial

Background

Corcept Therapeutics is contesting the admissibility of a former federal judge's expert testimony in Teva's antitrust lawsuit over the generic version of Korlym.

Company-level read

Ticker impact

$TEVABullishMedium confidence
Context

Teva is the opposing party in the antitrust lawsuit and benefits from Corcept's attempt to block expert testimony.

Expected impact

potential upside as market anticipates a stronger position for Teva in the case

Evidence & confidence

If the court limits Corcept's expert evidence, Teva's claims of anticompetitive behavior may be viewed more credible.

Market effects

Sector

Highlights ongoing antitrust risk in the pharmaceutical generic market.

Regional

May affect investor sentiment toward US-listed pharma stocks involved in patent litigation.

Global

Limited to the two companies; no broader macro impact.

Counterpoint

What could challenge this read

The motion may be dismissed, leaving Corcept's defense intact and limiting any upside for Teva.

Key entities

  • Company
    Corcept Therapeutics Inc.

    Plaintiff seeking to block expert testimony.

  • Company
    Teva Pharmaceutical Industries Ltd.

    Defendant alleging antitrust violations.

  • Individual
    Kathleen O’Malley

    Retired Federal Circuit judge retained as expert by Teva.

Read at source← All news

Related articles

OCT 13
$TEVAHigh

Teva wins FDA approval for schizophrenia injection

Teva Pharmaceuticals received FDA approval for a new injection form of olanzapine, an antipsychotic drug for schizophrenia. The company claims this could improve patient adherence compared to daily oral treatment, potentially reducing relapse risks. Olanzapine is the most widely prescribed atypical antipsychotic.

lifesciencesweden.se1 min
OCT 13
$TEVAHigh

USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

Teva, in partnership with Medincell, received USFDA approval for Weltruza, a once-monthly schizophrenia injection. Teva expects to launch the drug in the US soon. Medincell's technology enables extended-release medication. Analysts note potential for improved treatment adherence. Medincell may receive up to $112 million in milestone payments and royalties. Teva's shares rose 2% in Tel Aviv; Medincell's shares gained 16.9% in Paris.

medicaldialogues.in2 min
OCT 12
$TEVAHigh

FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' once-monthly olanzapine injection (Weltruza) for adults with schizophrenia. The subcutaneous injection uses novel technology for steady release, eliminating post-injection monitoring. The approval was based on the Phase 3 SOLARIS trial, showing significant symptom reduction and a safety profile consistent with oral olanzapine.

drugtopics.com3 min
OCT 12
$TEVAHigh

FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine injection, received FDA approval for treating schizophrenia. The treatment requires no loading doses or postinjection monitoring. It will be available in doses of 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine doses. The approval was based on the SOLARIS trial, which showed significant improvements in symptoms compared to placebo.

pharmacytimes.com3 min
OCT 12
$TEVAMed

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injection for schizophrenia. Shares rose 4.7% on Oct. 9. The drug will launch in the U.S. soon, offering an alternative to daily oral treatments. Teva's Uzedy, another schizophrenia treatment, saw sales surge 51% YoY to $140M in H1 2026. Teva also progresses with its branded pipeline, including duvakitug for inflammatory bowel diseases.

zacks.com6 min